Facial Cutaneous Squamous Cell Carcinoma in Situ
Conditions
Keywords
skin cancer, facial skin cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma in Situ, Cutaneous Squamous Cell Carcinoma in Situ, Facial Cutaneous Squamous Cell Carcinoma in Situ
Brief summary
The goal of this clinical trial is to test how safe and effective it is to treat early form of cancer cells found in the upper skin layer of the face, using a light-sensitive cream used in combination with a light source. The main questions this trial aims to answer are: * to confirm using laboratory testing, how much of the affected facial skin cancer section the treatment was able to remove, and; * seeing how many participants had no remaining affected facial skin cancer sections after treatment. Participants who qualify will be asked to complete 12 visits in total and will receive a total of two treatments, after voluntarily consent has been given.
Detailed description
In the study, participants will be asked to complete the following: * Provide basic personal information (including date of birth, gender, race and ethnicity) * Provide their medical/ surgical history and perform a medical exam (including but not limited to physical exam, skin type, vital signs, height, weight and urine pregnancy test collection) * Follow study rules such as avoiding certain medications and treatments * Allow photographs of the area of skin cancer being treated on the face * Provide information on any medications, treatments or reactions that started after the study began * Allow two treatments on the skin cancer area of the face using a light-sensitive cream used in combination with a light source * Allow clinical documentation of the treatment, such as how well the treatment was tolerated, any skin reaction or side effects * Allow surgery to remove the skin cancer area from the face for Laboratory testing To qualify for this trial, participants must: * be an adult (18 years of age or older) * give voluntary written consent * have a recently diagnosed (less than six months from first visit) skin cancer area on the face that meets surgery size requirements * be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas * (if female) not be pregnant before and during the study and agree to use acceptable forms of birth control * confirm they are not sensitive to any of the study treatment ingredients All surgery samples collected from the participants towards the end of the study will be sent to a laboratory for testing. All photographs of the treatment area collected during the study will be used as study data. All participants have the right to refuse further participation in the study at any time.
Interventions
COMBINATION_PRODUCTAminolevulinic Acid 20% Topical Solution with Blue Light
Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
Sponsors
Sun Pharmaceutical Industries Limited
The Center for Clinical and Cosmetic Research
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must be an adult (18 years of age or older) * Voluntary written consent required * Must have a recently diagnosed (no more than six months from first study visit) facial isSCC lesion that meets surgery excision size requirements * Cannot have other dermatological disease in the isSCC target area * Must be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas * If female, cannot be pregnant before and during the study and agree to use acceptable forms of birth control
Exclusion criteria
* Sensitive to any of the study treatment ingredients * Pregnant or lactating * Medical laboratory evidence of other non-isSCC tumor in the target lesion biopsy specimen * History of recurrence in the target isSCC lesion * Medical laboratory evidence of certain growth patterns in the target lesion biopsy specimen * Chronic medical condition that in the Investigators opinion will interfere in the trial or affect participant safety
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Histological Clearance of treated isSCC lesion | Up to 16 weeks | Histological clearance is defined as the absence of detectable evidence of isSCC tumor cell nests by the central pathology reports |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with clinical clearance of treated isSCC lesion | through treatment completion, an average of 12 weeks | Complete Clinical Clearance will be measured by the Investigator and is defined as when there is no clinically visible lesion remaining at the site. |
| Local Skin Response Scale | up to 16 weeks | Observations and changes noted in the aesthetic appearance (Erythema, Flaking/ Scaling, Crusting, Swelling, Vesiculation/ Pustulation, Erosion/ Ulceration) of the treated isSCC lesion will each be graded on a scale of 0 to 4, with 0 as no presence and 4 as a severe outcome. |
Countries
United States
Outcome results
None listed